Who are CombAct-HIB®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hib conjugate vaccine, Hib (Hiberix™), Hiberix™ Vaccine, LBVH0101 (Hib vaccine), Hib Vaccine Group, Hib conjugate vaccine (ActHIB).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/combact-hib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

CombAct-HIB® — Competitive Intelligence Brief

CombAct-HIB® (CombAct-HIB®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Conjugate vaccine Haemophilus influenzae type b polysaccharide capsule Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

CombAct-HIB® (CombAct-HIB®) — Sanofi Pasteur, a Sanofi Company. CombAct-HIB is a combination vaccine that provides immunization against Haemophilus influenzae type b (Hib) by stimulating antibody production against the bacterial polysaccharide capsule.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CombAct-HIB® TARGET	CombAct-HIB®	Sanofi Pasteur, a Sanofi Company	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule
Hib conjugate vaccine	Hib conjugate vaccine	Public Health England	marketed	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule
Hib (Hiberix™)	Hib (Hiberix™)	GlaxoSmithKline	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule (PRP)
Hiberix™ Vaccine	Hiberix™ Vaccine	LG Life Sciences	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule (PRP)
LBVH0101 (Hib vaccine)	LBVH0101 (Hib vaccine)	LG Life Sciences	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule (PRP)
Hib Vaccine Group	Hib Vaccine Group	Beijing Minhai Biotechnology Co., Ltd	phase 3	vaccine	Haemophilus influenzae type b polysaccharide capsule
Hib conjugate vaccine (ActHIB)	Hib conjugate vaccine (ActHIB)	GlaxoSmithKline	phase 3	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Conjugate vaccine class)

GlaxoSmithKline · 26 drugs in this class
Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
CanSino Biologics Inc. · 3 drugs in this class
MCM Vaccines B.V. · 3 drugs in this class
Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
PT Bio Farma · 2 drugs in this class
LG Life Sciences · 2 drugs in this class
Walvax Biotechnology Co., Ltd. · 2 drugs in this class
Heinrich-Heine University, Duesseldorf · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CombAct-HIB® — Competitive Intelligence Brief. https://druglandscape.com/ci/combact-hib. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab